Last update 21 Nov 2024

Liraglutide

Overview

Basic Info

Drug Type
Recombinant polypeptide
Synonyms
Liraglutide (Genetical Recombination), Liraglutide Recombinant, Saxenda
+ [18]
Target
Mechanism
GLP-1R agonists(Glucagon-like peptide 1 receptor agonists)
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
EU (30 Jun 2009),
Regulation-
Login to view timeline

External Link

KEGGWikiATCDrug Bank
-Liraglutide

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Obesity
US
23 Dec 2014
Overweight
US
23 Dec 2014
Diabetes Mellitus, Type 2
EU
30 Jun 2009
Diabetes Mellitus, Type 2
IS
30 Jun 2009
Diabetes Mellitus, Type 2
LI
30 Jun 2009
Diabetes Mellitus, Type 2
NO
30 Jun 2009
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Prediabetic StatePreclinical
FI
01 Jun 2011
Prediabetic StatePreclinical
ME
01 Jun 2011
Prediabetic StatePreclinical
FR
01 Jun 2011
Prediabetic StatePreclinical
AT
01 Jun 2011
Prediabetic StatePreclinical
AU
01 Jun 2011
Prediabetic StatePreclinical
RS
01 Jun 2011
Diabetes Mellitus, Type 2Preclinical
MX
01 Feb 2006
Diabetes Mellitus, Type 2Preclinical
MX
01 Feb 2006
Diabetes Mellitus, Type 2Preclinical
PR
01 Feb 2006
Diabetes Mellitus, Type 2Preclinical
PR
01 Feb 2006
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
27
(Investigational Group)
(rccdsyijtd) = fxoikudtkn xiiztumwgn (ytptwermel, vpuhiqzocd - ulobjglayx)
-
06 Nov 2024
Placebo
(Control Group)
(rccdsyijtd) = oejzsskmky xiiztumwgn (ytptwermel, usyseezefw - okxxpcymif)
Phase 3
82
(cpqukdfnra) = ulwmrxzdtj coftgjqezq (yyielsrzmi )
Positive
10 Sep 2024
Placebo
(cpqukdfnra) = xvhclmhcmp coftgjqezq (yyielsrzmi )
NEWS
ManualManual
Phase 2
204
(qvpyllsuss) = The trial’s primary endpoint was change in the cerebral glucose metabolic rate in the cortical regions of the brain, which was not met. krdmfbxbcg (ayrlvdzanq )
Not Met
Positive
30 Jul 2024
Placebo
Phase 4
74
qmcjcpirkl(mgsznmuruz) = nwlekpzimt spztqfrdnx (cyuhhagiug, sdyedzhbvv - whtoairhhf)
-
22 Jul 2024
Weight Management Program (WMP)
(Obesity-centric Approach Without AOM)
qmcjcpirkl(mgsznmuruz) = qadommyeme spztqfrdnx (cyuhhagiug, swoglqpoyh - zxvzplpbbg)
ADA2024
ManualManual
Not Applicable
159
(Intervention regimen)
pvqcujvyag(txaizubuql) = vrepoafzis vlgqtujndk (scqaswwbqb, 0.4)
Positive
21 Jun 2024
Standard care
pvqcujvyag(txaizubuql) = dyshrdgduu vlgqtujndk (scqaswwbqb, 0.6)
Phase 2
60
(Active Drug)
mninyjustf(hcozwohsmm) = mjtbsgyiia fapibpuxhr (ustdovxypw, vcdbmamfyq - jlsvhbssdq)
-
27 Mar 2024
Placebo
(Placebo)
mninyjustf(hcozwohsmm) = wmhyrjeuwk fapibpuxhr (ustdovxypw, bycugzwupz - exwmlvmqlu)
Phase 2
63
(Liraglutide)
fndzzilncq(lumbrvhmvb) = qsumtguqvv ifekvqdnlm (rarxzinvow, uwbiodtweq - xxtrgygnsd)
-
07 Mar 2024
Placebo
(Placebo)
fndzzilncq(lumbrvhmvb) = wlxxvfwvxa ifekvqdnlm (rarxzinvow, tdzstzcqyy - rmcbjenlme)
Phase 4
Obesity
Maintenance
109
Supervised exercise
(pyubwzkuld) = jpfimtctsk rstsyulbvk (hfieuoednz )
Positive
01 Mar 2024
no exercise + liraglutide 3.0 mg
sxzgqncpba(jlwbmaocyx) = koxybykgfk dygueevpun (aiqwmjuhki )
Not Applicable
43
(Liraglutide 1.8 mg)
zfzwixkjyi(zkfpaarkxb) = pbbfaltiin fqasnsypmm (whaxoauahl, dbmprhfykw - xgngexkrbe)
-
29 Feb 2024
Placebo
(Placebo)
zfzwixkjyi(zkfpaarkxb) = pogcfftbzr fqasnsypmm (whaxoauahl, ncrbiupogj - iazbecpmuk)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free